Intraventricular administration of recombinant tissue plasminogen activator for intraventricular hemorrhage in the newborn
β Scribed by Mete Akisu; Mehmet Yalaz; Sertac Arslanoglu; Nilgun Kultursay
- Publisher
- Springer-Verlag
- Year
- 2003
- Tongue
- English
- Weight
- 130 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0344-5607
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The in vitro functional properties of recombinant tissue plasminogen activator (rt-PA), its biodistribution in mice, and its pharmacokinetics and clot localization properties in dogs have been investigated after labeling rt-PA with 111In. The rt-PA was coupled with the bicyclic anhydride of DTPA usi
The mechanism by which intravesical recombinant tissue plasminogen activator (rTPA) prevents tumor cell adherence to injured bladder surfaces, and the optimal parameters for the in vivo use of rTPA for adherence prevention, were evaluated. Intravesical rTPA decreased tumor cell adherence to sites of
Recombinant tissue-type plasminogen activator (rt-PA) is indicated for the treatment of acute myocardial infarction as a dose of up to 100 mg. Several clinical trials have suggested that higher patency rates can be achieved with a rapid drug administration. A study was conducted in rabbits to determ